drugset / Trial / NCT00535145
Study to Measure the Safety of Paliperidone ER (Extended-release) in Patients With Liver Disease
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the tolerability and safety of paliperidone ER (extended-release) in doses between 3 milligrams per day and 12 milligrams per day in the treatment of patients with schizophrenia or schizoaffective disorder and liver disease.
Timeline
- Start
- 2007-10
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paliperidone | Unknown | 3 mg | Oral |
| Subject | Paliperidone | Unknown | 12 mg | Oral |